NCT06816394 - Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

April 30, 2029

Conditions

Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma

Interventions

DRUG

Tarlatamab

All subjects will receive a step dose (1 mg tarlatamab) on cycle 1 day 1 administered as a 60-minute intravenous (IV) infusion then 10 mg tarlatamab IV administered on cycle 1 day 8, cycle 1 day 15, and every 2 weeks (Q2W) thereafter.

Trial Locations (1)

100056

National Taiwan University Hospital, Taipei